Cargando…

Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein

The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and models the resistance phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy. A TaqMan low-density array (TLDA) was used to characterise the expression of 380 genes ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stordal, Britta, Hamon, Marion, McEneaney, Victoria, Roche, Sandra, Gillet, Jean-Pierre, O’Leary, John J., Gottesman, Michael, Clynes, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394717/ https://www.ncbi.nlm.nih.gov/pubmed/22792399 http://dx.doi.org/10.1371/journal.pone.0040717

Ejemplares similares

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
por: Dorris, Emma R., et al.
Publicado: (2016)

Mitochondria P-glycoprotein confers paclitaxel resistance on ovarian cancer cells
por: Guo, Weina, et al.
Publicado: (2019)

Paclitaxel and SN‐38 Overcome Cisplatin Resistance of Ovarian Cancer Cell Lines by Down‐regulating the Influx and Efflux System of Cisplatin
por: Komuro, Yuuki, et al.
Publicado: (2001)

Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines
por: Busschots, Steven, et al.
Publicado: (2014)

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines
por: Kazmierczak, Dominika, et al.
Publicado: (2022)

CD10(−)/ALDH(−) cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy
por: Ffrench, Brendan, et al.
Publicado: (2017)

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
por: Ribeiro, J. R., et al.
Publicado: (2016)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies
por: McDermott, Martina, et al.
Publicado: (2014)

Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells
por: Egan, Karl, et al.
Publicado: (2011)

Max-plus methods for nonlinear control and estimation
por: McEneaney, William M
Publicado: (2006)

Armband Sensors Location Assessment for Left Arm-ECG Bipolar Leads Waveform Components Discovery Tendencies around the MUAC Line
por: Escalona, Omar, et al.
Publicado: (2022)

BRASH SYNDROME: AN UNDER RECOGNISED CAUSE OF COMPLETE HEART BLOCK IN THE ELDERLY
por: Savage, Patrick, et al.
Publicado: (2020)

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
por: Sherman-Baust, Cheryl A, et al.
Publicado: (2011)

Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells
por: Szenajch, Jolanta, et al.
Publicado: (2020)

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
por: Mesquita, Bárbara, et al.
Publicado: (2005)

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity
por: Gamarra-Luques, Carlos D, et al.
Publicado: (2014)

Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines
por: Chauhan, S S, et al.
Publicado: (2003)

The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer
por: Bates, Mark, et al.
Publicado: (2020)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression
por: Lee, Jung-Pil, et al.
Publicado: (2013)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Stochastic analysis, control, optimization and applications: a volume in honor of W.H. Fleming
por: McEneaney, William, et al.
Publicado: (1999)

Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line
por: Enokida, Hideki, et al.
Publicado: (2002)

Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein
por: Nunes, Mariana, et al.
Publicado: (2021)

Transcriptome profile of OVCAR3 cisplatin-resistant ovarian cancer cell line
por: Sakhare, Shruti S, et al.
Publicado: (2014)

The Mechanism of Acquired Resistance to Cisplatin by a Human Ovarian Cancer Cell Line
por: Kikuchi, Yoshihiro, et al.
Publicado: (1988)

Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines
por: Al Balushi, Najwa, et al.
Publicado: (2022)

Thrombus formation on a defibrillator lead with conductor externalization
por: McKeag, Nicholas A., et al.
Publicado: (2015)

Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes.
por: Shen, D. W., et al.
Publicado: (1995)

Corrigendum: Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein
por: Nunes, Mariana, et al.
Publicado: (2022)

The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival
por: Rae, Sophie, et al.
Publicado: (2022)

Increased FOXM1 Expression by Cisplatin Inhibits Paclitaxel-Related Apoptosis in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma (OSCC) Cell Lines
por: Choi, Hyeong Sim, et al.
Publicado: (2020)

Numerical methods for optimal control problems
por: Falcone, Maurizio, et al.
Publicado: (2018)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
por: McClay, E. F., et al.
Publicado: (1994)

Cisplatin Resistant Patterns in Ovarian Cell Line Using FTIR and Principle Component Analysis
por: Zendehdel, Rezvan, et al.
Publicado: (2012)

Cathepsin L-mediated resistance of paclitaxel and cisplatin is mediated by distinct regulatory mechanisms
por: Zhao, Yifan, et al.
Publicado: (2019)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vlhbraod30i06v4mj625f0vi42